Vivacta Biotechnology, a Shanghai-based firm pioneering in vivo CAR-T therapies, has successfully secured over $50 million in a combined Series A and Series A+ financing round. The funding was co-led by prominent investors Loyal Valley Capital and Decheng Capital, signaling strong confidence in the company's innovative approach. This significant capital infusion is set to accelerate the development of Vivacta's groundbreaking treatments for cancer and autoimmune diseases.
Strategic Investment to Propel Clinical Development
The financing rounds attracted a distinguished syndicate of global industrial and specialist biotechnology investors, underscoring the widespread recognition of Vivacta's potential. Loyal Valley Capital led the Series A, while Decheng Capital spearheaded the Series A+ round. Other notable participants included OrbiMed, Hankang Capital, and Eisai Innovation Inc., alongside continued support from existing shareholders like Qiming Venture Partners.
Proceeds from this substantial investment are earmarked for several key strategic initiatives to drive the company's growth. A primary focus will be advancing the clinical trials for its lead candidate, GT801, and supporting its subsequent regulatory submission and approval process. The capital will also facilitate the expansion of the research team and accelerate Vivacta's global footprint in the competitive in vivo CAR-T field.
Pioneering In Vivo CAR-T Therapy
At the heart of Vivacta's mission is its flagship product, GT801, a next-generation in vivo CAR-T therapy. This innovative treatment is designed to engineer therapeutic cells directly within the patient's body, offering a potentially transformative option for various conditions. The therapy has shown significant promise in early studies for treating both hematologic malignancies and complex autoimmune diseases.
The company's progress with GT801 has already garnered attention within the scientific community, bolstering investor confidence. Initial human data from early clinical studies demonstrated a promising safety and efficacy profile for the therapy. These encouraging results were recently presented in an oral report at the American Society of Hematology Annual Meeting in December 2025.
Leadership and Vision for the Future
Dr. Liu Yarong, the Founder and CEO of Vivacta, expressed deep gratitude for the support from the company's new and existing investors. He emphasized Vivacta's commitment to advancing its innovative cell therapies to address significant unmet medical needs. Dr. Liu highlighted that GT801 could offer a transformative treatment option for patients with hematological malignancies and autoimmune diseases.
In conjunction with the financing, Vivacta has strengthened its corporate governance by welcoming new members to its board of directors. Mr. Xie Ronggang from Loyal Valley Capital and a partner from DC Global Ventures have joined the board. Their inclusion brings valuable expertise and strategic oversight as the company enters its next phase of clinical development and global expansion.
This successful funding round marks a pivotal moment for Vivacta Biotechnology, providing the necessary resources to advance its pioneering therapies through critical clinical stages. The strong backing from a consortium of leading global investors validates the potential of its in vivo CAR-T platform. With this capital, Vivacta is well-positioned to bring its innovative treatments closer to patients in need worldwide.